1. Home
  2. SERA vs TENX Comparison

SERA vs TENX Comparison

Compare SERA & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sera Prognostics Inc.

SERA

Sera Prognostics Inc.

N/A

Current Price

$2.09

Market Cap

75.2M

Sector

Health Care

ML Signal

N/A

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$1.92

Market Cap

71.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SERA
TENX
Founded
2008
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Precision Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
75.2M
71.1M
IPO Year
2021
2001

Fundamental Metrics

Financial Performance
Metric
SERA
TENX
Price
$2.09
$1.92
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$29.67
AVG Volume (30 Days)
21.3K
4.7M
Earning Date
05-06-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
32.32
N/A
EPS
N/A
N/A
Revenue
$81,000.00
N/A
Revenue This Year
$554.81
N/A
Revenue Next Year
$517.27
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.19
N/A
52 Week Low
$1.56
$1.31
52 Week High
$3.95
$19.40

Technical Indicators

Market Signals
Indicator
SERA
TENX
Relative Strength Index (RSI) 54.67 27.98
Support Level $1.88 $1.31
Resistance Level $2.12 $2.22
Average True Range (ATR) 0.07 0.15
MACD 0.00 0.41
Stochastic Oscillator 59.03 43.87

Price Performance

Historical Comparison
SERA
TENX

About SERA Sera Prognostics Inc.

Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: